Medical Condition News

RSS

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

A computer-based diabetes simulation tool developed by University of Virginia researchers is now commercially available, thanks to a partnership with the Charlottesville-based medical research firm The Epsilon Group. The simulator is the only protocol that has been accepted by the U.S. Food and Drug Administration as an alternative to animal testing of Type 1 diabetes control strategies.

29 Jun 2011

Insufficient sleep can reduce benefit of hormones released during sleep

Nearly half of all Americans reported having difficulty sleeping. The Center for Disease Control and Prevention has reported that about 35% of people surveyed in 12 states said they slept less than 7 hours a night on average.

29 Jun 2011

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.

29 Jun 2011

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.

28 Jun 2011

Start of clinical validation study of Down’s syndrome diagnostic test

In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG and LifeCodexx AG have begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing.

28 Jun 2011

New insights into 'sundowning' syndrome

New research provides the best evidence to date that the late-day anxiety and agitation sometimes seen in older institutionalized adults, especially those with dementia, has a biological basis in the brain.

28 Jun 2011

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Bio-Nucleonics' lead product Strontium Chloride Sr-89 Injection USP (Strontium-89), which is the generic version of Metastron®, is an option to consider for metastatic cancer bone pain therapy, typically caused by advanced stage breast, prostate or lung cancer.

28 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

28 Jun 2011

Federal Ministry of Health supports radionuclide production at Research Neutron Source

The German Federal Ministry of Health has awarded more than one million euros in research and development funding for the efficient production of an important cancer diagnostic agent at the research neutron source FRM II. In a 2009 feasibility study, the Technische Universitaet Muenchen demonstrated that due to the high neutron flux the neutron source in Garching can produce about half of the European demand of the radioisotope molybdenum-99.

28 Jun 2011

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.

28 Jun 2011

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

Why is antibody diversity important? Think about it like this, said Myron Goodman, who is an author on the paper: "Why don't you die when I sneeze? It's because you have a powerful immune system. And the way to get a decent immune system is for your body to have a way to respond to insults it has never seen before."

28 Jun 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

Study shows how binge drinking could cause serious brain damage in young adults

It's considered a rite of passage among young people - acting out their independence through heavy, episodic drinking. But a new University of Cincinnati study, the first of its kind nationally, is showing how binge drinking among adolescents and young adults could be causing serious damage to a brain that's still under development at this age.

28 Jun 2011

Study links physiological responses to anger with reduction of empathy after severe TBI

Egocentric, self-centred, and insensitive to the needs of others: these social problems often arise in people with severe traumatic brain injury (TBI) and have been attributed in part to a loss of emotional empathy, the capacity to recognise and understand the emotions of other people.

28 Jun 2011

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.

28 Jun 2011

NUROMOL non-prescription painkiller now available in pharmacies across the UK

A new non-prescription painkiller is now available in pharmacies across the UK, heralding the first UK painkiller combination of ibuprofen and paracetamol in 'over-the-counter' pain relief.

28 Jun 2011

Enrollment complete in BIOTRONIK 4EVER clinical trial for treatment of peripheral vascular disease

BIOTRONIK announced today that the full cohort of 120 patients has been successfully enrolled into the physician-initiated 4EVER clinical study. Follow up is scheduled at 1, 6 and 12 months, with immediate and 6 month results potentially available in January 2012.

28 Jun 2011

Number of adults with diabetes doubled over past three decades, study shows

The number of adults with type 2 diabetes has doubled worldwide over the last three decades, rising from 153 million in 1980 to 347 million, "a sign that the epidemic will impose an ever-greater cost burden on health systems," according to a study published on Saturday in the Lancet, the Wall Street Journal reports.

28 Jun 2011

Medical Condition News

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

Insufficient sleep can reduce benefit of hormones released during sleep

FDA clears Nuvo's IND for Lidocaine Spray formulation

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Start of clinical validation study of Down’s syndrome diagnostic test

New insights into 'sundowning' syndrome

Bio-Nucleonics' generic Metastron, an option for metastatic cancer bone pain therapy

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Federal Ministry of Health supports radionuclide production at Research Neutron Source

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

Inefficiency of activation-induced deoxycytidine deaminase is good for the immune system

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

EAS, ESC develop new European guidelines to manage dyslipidaemias

Study shows how binge drinking could cause serious brain damage in young adults

Study links physiological responses to anger with reduction of empathy after severe TBI

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

NUROMOL non-prescription painkiller now available in pharmacies across the UK

Enrollment complete in BIOTRONIK 4EVER clinical trial for treatment of peripheral vascular disease

Number of adults with diabetes doubled over past three decades, study shows

How can machine learning accelerate neuroscience behavior studies?

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Latest News